Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements-Reference-Cited by-同舟云学术

Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements

Published:2018-07 Issue: Volume:347 Page:350-359
ISSN:0166-4328
Container-title:Behavioural Brain Research
language:en
Short-container-title:Behavioural Brain Research

Author:

Tsunekawa Hiroko,Takahata Kazue,Okano Motoki,Ishikawa Toshiko,Satoyoshi Hiroshi,Nishimura Tetsuya,Hoshino Naoya,Muraoka Shizuko

Publisher

Elsevier BV

Subject

Behavioral Neuroscience

Reference60 articles.

1. Parkinson’s disease: clinical features and diagnosis;Jankovic;J. Neurol. Neurosurg. Psychiatry,2008

2. Invited article: nervous system pathology in sporadic Parkinson disease;Braak;Neurology,2008

3. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature;Ahlskog;Mov. Disord.,2001

4. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology;Pahwa;Neurology,2006

5. Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding;Bédard;Brain Res.,1986

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies;Cells;2022-11-23

2. Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence;Frontiers in Pharmacology;2022-04-07

3. Color-convertible fluorescent nanoprobe for Parkinson’s disease diagnosis;Chemical Engineering Journal;2022-02

4. The Role of Monoamine Oxidase B Inhibitors in the Treatment of Parkinson’s Disease – An Update;CNS & Neurological Disorders - Drug Targets;2021-12-31

5. The Rodent Models of Dyskinesia and Their Behavioral Assessment;Frontiers in Neurology;2019-10-11